Related Experiment Video

Updated: Jul 21, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

Strategies Beyond 3rd EGFR-TKI Acquired Resistance: Opportunities and Challenges

Xuexue Zhou1,2, Liang Zeng2, Zhe Huang2,3

  • 1Medical College, Jishou University, Jishou, China.

Cancer Medicine
|May 5, 2025
PubMed

Insights

Third-generation EGFR-TKI revolutionized non-small cell lung cancer treatment, but resistance is common. This review explores resistance mechanisms and new therapies to overcome acquired resistance, focusing on central nervous system metastases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) mutations drive non-small cell lung cancer (NSCLC).
  • Third-generation EGFR tyrosine kinase inhibitors (EGFR-TKI) are first-line treatments for advanced EGFR-mutated NSCLC.
  • Acquired resistance to EGFR-TKI presents a significant clinical challenge.

Purpose of the Study:

  • To systematically review molecular mechanisms of acquired resistance to third-generation EGFR-TKI in NSCLC.
  • To focus on clinical challenges posed by central nervous system (CNS) metastases.
  • To evaluate diagnostic modalities and emerging therapeutic strategies to overcome resistance.

Main Methods:

  • Systematic literature review of preclinical and clinical studies.
  • Categorization of resistance mechanisms into EGFR-dependent (on-target) and EGFR-independent (off-target) pathways.
  • Evaluation of diagnostic tools and novel therapeutic approaches.

Main Results:

  • Resistance mechanisms include on-target mutations (e.g., C797S) and off-target pathways (e.g., MET amplification, HER2 activation).
  • Central nervous system (CNS) metastases present unique clinical challenges.
  • Emerging strategies include fourth-generation EGFR-TKI, combination therapies, and antibody-drug conjugates (ADCs).

Conclusions:

  • Understanding resistance mechanisms is crucial for developing effective treatment strategies.
  • Novel therapies and combination approaches show promise in overcoming acquired resistance.
  • Ongoing clinical trials are vital for advancing treatment paradigms for EGFR-mutated NSCLC.
Keywords:
EGFR mutationNSCLCacquired resistance mechanismstherapeutic strategiesthird‐generation EGFR‐TKI

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397